Biotech Values

[masterlongevity]

The ph 2 data showed a statistically significant benefit of bapineuzumab over PBO in the ApoE4 non-carrier population on almost every measure. The caveats are that this was a post-hoc analysis and the PBO decline was a little worse than historical average.

In the same post-hoc, bapineuzumab did not show benefit over PBO on ANY measure in the carrier population

Part of the retrospective rationale is that maybe the carrier population has a more aggressive disease and needs to be treated earlier.